Name: Levodopa
Brand: Selleck Chemicals
SKU: S1726
Rating: 5 (3 reviews)

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Dopamine Receptor Inhibitors	MPTP Hydrochloride Trifluoperazine Trifluoperazine 2HCl Penfluridol Sulpiride Levosulpiride SCH-23390 hydrochloride Domperidone Rotundine Azaperone

Chemical Information, Storage & Stability

Molecular Weight	197.19	Formula	C₉H₁₁NO₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	59-92-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	L-DOPA			Smiles	C1=CC(=C(C=C1CC(C(=O)O)N)O)O

Solubility

In vitro
Batch:

5%TFA : 6.03 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Clear solution	5%5%TFA 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.15mg/ml (0.76mM)	Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clarified 5%TFA stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% 5%TFA 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.15mg/ml (0.76mM)	Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clear 5%TFA stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Dopamine receptor
In vitro	Levodopa produces at 25-200 μM concentrations a dose-dependent reduction of 3H-DA uptake in foetal rat midbrain cultures. This compound results in a decrease in the number of viable cells and tyrosine hydroxylase (TH) positive neurones, plus disruption of the overall neuritic network. It induces dyskinesia in the absence of dopamine by excessive inhibition of neurons of the putamen-globus pallidus (GPe) projection and subsequent disinhibition of the globus pallidus (GPe). This chemical results in a decrease in cytochrome oxidase messenger RNA expression in the globus pallidus (GPi).
In vivo	Levodopa elicits the development of a variety of abnormal movements in monkeys with parkinsonism induced by the neurotoxin MPTP. This compound administrations result in an ectopic induction of the dopamine D3receptor expression in the CdPu in 6-OHDA-lesioned rats. This chemical (50 mg/kg) increases anandamide concentrations throughout thebasal ganglia via activation of dopamine D1/D2 receptors in intact rats. It produces increasingly severe oro-lingual involuntary movements which are attenuated by the cannabinoid agonist R(+)-WIN55,212-2 (1 mg/kg) in lesioned rats. This compound administration reverses the up-regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that it reaches a biologically active concentration at the basal ganglia.
References	[1] https://pubmed.ncbi.nlm.nih.gov/8499605/ [2] https://pubmed.ncbi.nlm.nih.gov/15102749/ [3] https://pubmed.ncbi.nlm.nih.gov/90966399/ [4] https://pubmed.ncbi.nlm.nih.gov/14511339/ [5] https://pubmed.ncbi.nlm.nih.gov/9585350/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05094011	Not yet recruiting	Idiopathic Parkinson''s Disease	Taiwan Mitochondrion Applied Technology Co. Ltd.	March 1 2025	Phase 1
NCT06284629	Not yet recruiting	Parkinson Disease	Rigshospitalet Denmark\|Odense University Hospital\|Zealand University Hospital	September 1 2024	Not Applicable
NCT05558189	Not yet recruiting	Parkinson Disease	Stanford University	August 20 2024	Not Applicable
NCT06339034	Not yet recruiting	Parkinson Disease	State University of New York at Buffalo\|The Cure Parkinson''s Trust	June 2024	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Levodopa Dopamine Receptor agonist

Chemical Structure

Molecular Weight: 197.19